ESR Essentials: staging and restaging with FDG-PET/CT in oncology—practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging - Summary - MDSpire
Advertisement
ESR Essentials: staging and restaging with FDG-PET/CT in oncology—practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging
To provide practice recommendations for the use of [18F]FDG-PET/CT in oncology, specifically focusing on its role in staging, restaging, and treatment monitoring.
Key Findings:
[18F]FDG-PET/CT has high sensitivity for tumor detection but is not tumor-specific, which can lead to misinterpretations.
It significantly alters therapeutic management in about one-third of patients, highlighting its clinical importance.
[18F]FDG-PET/CT is crucial for evaluating disease response and planning surgical procedures, providing essential insights for treatment adjustments.
Interpretation:
[18F]FDG-PET/CT provides essential functional imaging that complements anatomical imaging, thereby improving the evaluation of cancer treatment responses.
Limitations:
Lower spatial resolution compared to CT or MRI.
False negatives in subcentimeter nodules due to low signal detection.
False positives may occur from inflammatory or infectious conditions, such as infections or autoimmune diseases.
Conclusion:
The integration of [18F]FDG-PET/CT in oncology enhances diagnostic accuracy and treatment management, particularly for a wide range of cancers, not just the most prevalent ones.
